DeCure for Arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum
DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleArthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for arthrogryposis multiplex congenita 4, neurogenic, with agenesis of the corpus callosum is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Neurosciences · 2001 · 18 citations · open access
Corpus callosum agenesis
AbstractOBJECTIVE: The objectives are to analyse corpus callosum agenesis in children with various neurological problems in a hospital set-up, and to study the neurological and systemic abnormalities associated with this condition. METHODS: The children with various neurological problems who underwent computerized tomography brain from January 1993 to December 1997, and were found to have corpus callosum agenesis, formed the subjects of this study. These children were examined for any syndromic association, congenital infections or metabolic defects. RESULTS: Out of 2164 children who underwent computerized tomography brain, 22 had corpus callosum agenesis (1%). Most cases were not syndromic and 64% were males. Epileptic disorders were noted in about one third of cases. CONCLUSION: Corpus callosum agenesis an important anomaly in children with neurodevelopment handicaps, usually detected by neuroradiology.
Anaesthetic Management of an Obstetrical Patient with Arthrogryposis Multiplex Congenita
AbstractArthrogryposis Multiplex Congenita (AMC) describes a rare multifactorial syndrome caused by a variety of neurogenic and myopathic disorders first diagnosed at birth and often progressing to a state of significant disability. It includes abnormalities of the cardiovascular, respiratory, nervous and genitourinary systems. The syndrome is seen primarily in the paediatric population, and orthopedic procedures are common. There remains much confusion regarding diagnosis, aetiology, genetic probabilities, natural history and management.1-2 Occasionally an adult with this sydrome presents for an anaesthetic.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
